# Phase 2 Study of IDH305 in Low Grade Gliomas

> **NCT02987010** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Glioma

## Interventions

- **DRUG:** IDH305

## Key facts

- **NCT ID:** NCT02987010
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor did not want to move forward with protocol; study was never opened.
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987010, "Phase 2 Study of IDH305 in Low Grade Gliomas". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02987010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*